Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans

Diabetic Medicine

Volumn 27, Issue 7, 2010, Pages 830-837

  Sorensen L P ^a   Brock, B ^b   Mengel, A ^a   Rungby, J ^b   Moller, N ^a   Nielsen, S ^a   Volund A ^c   Schmitz, O ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

glucose metabolism; insulin; insulin analogues

Indexed keywords

C PEPTIDE; FATTY ACID; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; MALE; NORMAL HUMAN; SINGLE DRUG DOSE;

BODY MASS INDEX; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; YOUNG ADULT;

EID: 77954275040     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03026.x     Document Type: Article

References (23)

1. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004 53 : 1614 1620.
2. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999 16 : 332 338.
3. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di VA et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000 49 : 2142 2148.
4. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007 9 : 648 659.
5. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005 48 : 1988 1995.
6. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000 23 : 644 649.
7. Brunner GA, Sendhofer G, Wutte A, Ellmerer M, Sogaard B, Siebenhofer A et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes 2000 108 : 100 105.
8. Plank J, Bodenlenz M, Sinner F, Magnes C, Gorzer E, Regittnig W et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005 28 : 1107 1112.
9. Luzio S, Dunseath G, Peter R, Pauvaday V, Owens DR. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 2006 49 : 1163 1168.
10. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007 9 : 290 299.
11. Porcellati F, Rossetti P, Ricci NB, Pampanelli S, Torlone E, Campos SH et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care 2007 30 : 1261 1263.
12. Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007 30 : 2447 2452.
13. 3H]-glucose infusion and labelled or unlabelled glucose infusates. Diabet Med 1992 9 : 840 849.
14. Jensen MD, Caruso M, Heiling V, Miles JM. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes 1989 38 : 1595 1601.
15. Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia 2008 51 : 1790 1795.
16. Hompesch M, Troupin B, Heise T, Elbroend B, Endahl L, Haahr H et al. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab 2006 8 : 568 573.
17. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003 26 : 3080 3086.
18. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006 29 : 1269 1274.
19. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006 28 : 1569 1581.
20. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001 24 : 296 301.
21. Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008 30 : 1976 1987.
22. Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010 March 3 [Epub ahead of print].
23. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008 51 : 408 416.